Galena Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

GALE 1.37 +0.02 (1.48%)
price chart
Why Galena Biopharma, Inc. Stock Crashed By 52% in 2014
The overall market may be on pace to deliver solid gains for investors in 2014, but shareholders in Galena Biopharma (NASDAQ: GALE ) can do nothing but shake their head in disappointment with their stock down 52% for the year.
Related articles »  
Galena Biopharma Inc. Imploded in March -- Here's Why
What: Shares of Galena Biopharma (NASDAQ: GALE ) , a predominantly clinical-stage biopharmaceutical specialist focused on developing novel cancer vaccines, sank 23% in March (according to data from S&P Capital IQ) after the company reported ...
Today's Morning Insights: Hydrogenics Corporation (HYGS), Galena ...  WallStreet Scope
Galena Biopharma Inc (GALE) Releases Q4 Report Amid SEC Investigation
Aside from Galena Biopharma's earnings report, the company is currently under investigation by the SEC regarding a shareholder derivative suit.
Galena Biopharma (GALE) Falls: Stock Goes Down 6%
Galena Biopharma Receives Buy Rating from Noble Financial (GALE)  Dakota Financial News
Why Galena Biopharma Inc. Stock Sank 13% in November
What: Shares of Galena Biopharma (NASDAQ: GALE ) , a biopharmaceutical company focused on developing immunotherapies to treat cancer, sank 13% in November, based on data from S&P Capital IQ, following a weak earnings report and a questionable ...
Related articles »  
MLV Reiterates Buy on Galena Biopharma Inc Following Enrollment Expansion ...
MLV's healthcare analyst Vernon Bernardino came out with a few insights on Galena Biopharma Inc (NASDAQ:GALE), after the company announced expansion of targeted patient population for its ongoing Phase 2b clinical trial with NeuVax in combination ...
Could Galena Biopharma, Inc. Be Running Out of Money?
Today, we're going to take a closer look at small-cap biopharmaceutical company Galena Biopharma (NASDAQ: GALE ) to get a better bead on what its current cash situation looks like, to determine whether or not it could be running out of money, and to ...
Commentary On Drowning Stock's Performance - Galena Biopharma Inc ...
Fura Emeralds Inc. (GALE), a biopharmaceutical corporation developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, declared the pricing of an underwritten ...
Notable 52-Week Highs and Lows 3/13: (AMRN) (NXPI) (BMRN) High; (CTIC ...
Cantor Remains Cautious on Galena Biopharma Inc Following 4Q Earnings
In a research report issued today, Cantor analyst Mara Goldstein maintained a Sell rating on Galena Biopharma Inc (NASDAQ:GALE) with a $2.00 price target, following the company's fourth-quarter results, posting earnings of ($0.06) per share on revenues ...
Galena Biopharma (GALE) Tops Views  Wall Street Pit
Galena Biopharma Reports Fourth Quarter and Year End 2014 Financial Results  GlobeNewswire (press release)
MLV Pounds the Table on Galena Biopharma Inc
MLV analyst Vernon Bernardino was out pounding the table on Galena Biopharma Inc (NASDAQ:GALE) Monday, reiterating a Buy rating and a $5 price target, which implies an upside of 236% from current levels.
MLV & Co Analysts Give Galena Biopharma a $5.00 Price Target (GALE)  Dakota Financial News
Company Update (NASDAQ:GALE): Galena Biopharma Inc Expands Patient ...
Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that human ...
Galena expands patient population in NeuVax breast cancer trial (GALE)  Seeking Alpha (registration)
Galena Biopharma Expands Patient Population in NeuVax(TM) (nelipepimut-S ...  MarketWatch